The use of milbemycin oxime in a prophylactic anthelmintic programme to protect puppies, raised in an endemic area, against infection with Spirocerca lupi.

Spirocerca lupi is primarily a parasite of dogs and other carnivores. Clinical signs of infection are regurgitation, vomiting, weight loss, coughing and dyspnoea. Sudden death can also occur due to a ruptured aortic aneurysm. In this study, the Eastern Cape Province of South Africa was identified as an area with a high prevalence of S. lupi. A subsequent investigation, to evaluate the efficacy of milbemycin oxime as a prophylactic agent for canine spirocercosis, involved 58 puppies that were raised in this area in accordance with local husbandry procedures. Approximately half of the puppies served as untreated controls. Puppies in the treatment group received milbemycin oxime (minimum dose of 0.5mg/kg body weight) when they were between 2 and 6 weeks old. They then received five further treatments at approximately 28-day intervals. The treatment was orally administered in tablet form. After the sixth treatment, puppies from both the treated and control groups were euthanized and post-mortem examinations were performed. Twenty-four out of 27 dogs in the untreated control group had become infected by S. lupi. In comparison, only 19 out of 31 dogs in the treatment group had evidence of spirocercosis as demonstrated by aortic nodules. The prophylactic regimen reduced the severity of aortic lesions and prevented 86.5% of S. lupi from becoming established in the thoracic aorta. It also prevented 89.4% of S. lupi from becoming established in the oesophagus and significantly reduced the number of oesophageal nodules. Milbemycin oxime markedly reduced the level and severity of S. lupi infection in treated puppies raised in an endemic area of South Africa. It deserves further evaluation as a potential prophylactic treatment for spirocercosis.